Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers
- PMID: 15961980
- DOI: 10.1016/j.clpt.2005.02.006
Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers
Abstract
Objective: Our objective was to investigate the effect of the uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B15 genetic polymorphism on the pharmacokinetics and pharmacodynamics of lorazepam in basal, inhibited, and induced metabolic states in healthy normal volunteers.
Methods: Twenty-four healthy subjects were enrolled and grouped into UGT2B15*1/*1 or UGT2B15*2/*2 genotype groups. The pharmacokinetic and pharmacodynamic profiles of intravenous lorazepam were characterized before and after inhibition with 600 mg valproate once daily for 4 days and after induction with rifampin (INN, rifampicin) pretreatment (600 mg once daily for 10 days), with a washout period of 10 days between. The plasma concentrations of lorazepam and lorazepam glucuronide were analyzed before and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours after lorazepam administration by liquid chromatography-tandem mass spectrometry. Visual analog scale assessments and psychomotor coordination tests were administered before and up to 12 hours after drug administration.
Results: The UGT2B15*2/*2 group showed 0.58-fold (95% confidence interval, 0.43-0.72; P < .0001) lower systemic clearance during the basal state and 1.37-fold (95% confidence interval, 1.05-1.88; P = .037) higher area under the visual analog scale-time curve during the induced state compared with the UGT2B15*1/*1 group. The mean systemic clearance of lorazepam decreased by 20% in the inhibited state and increased by 140% in the induced state. During the inhibited or induced state, absolute values of clearance were consistently lower in the *2/*2 group, but the percent changes from baseline did not differ significantly by genotype.
Conclusions: Our results suggest that the UGT2B15*2 polymorphism is a major determinant of interindividual variability with respect to the pharmacokinetics and pharmacodynamics of lorazepam.
Similar articles
-
Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.Clin Pharmacol Ther. 2008 Apr;83(4):595-600. doi: 10.1038/sj.clpt.6100324. Epub 2007 Aug 8. Clin Pharmacol Ther. 2008. PMID: 17687269 Clinical Trial.
-
Rifampin reduces plasma concentrations and effects of zolpidem.Clin Pharmacol Ther. 1997 Dec;62(6):629-34. doi: 10.1016/S0009-9236(97)90082-5. Clin Pharmacol Ther. 1997. PMID: 9433391 Clinical Trial.
-
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.Clin Pharmacol Ther. 2003 Oct;74(4):334-40. doi: 10.1016/S0009-9236(03)00221-2. Clin Pharmacol Ther. 2003. PMID: 14534520 Clinical Trial.
-
Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam.J Clin Pharmacol. 1997 May;37(5):442-50. doi: 10.1002/j.1552-4604.1997.tb04322.x. J Clin Pharmacol. 1997. PMID: 9156377 Clinical Trial.
-
Pharmacokinetic alterations after severe head injury. Clinical relevance.Clin Pharmacokinet. 1998 Sep;35(3):209-21. doi: 10.2165/00003088-199835030-00004. Clin Pharmacokinet. 1998. PMID: 9784934 Review.
Cited by
-
Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms.Genes (Basel). 2023 Nov 6;14(11):2048. doi: 10.3390/genes14112048. Genes (Basel). 2023. PMID: 38002991 Free PMC article. Review.
-
The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes (Basel). 2023 May 16;14(5):1095. doi: 10.3390/genes14051095. Genes (Basel). 2023. PMID: 37239455 Free PMC article. Review.
-
Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.Eur J Clin Pharmacol. 2022 Oct;78(10):1667-1675. doi: 10.1007/s00228-022-03373-4. Epub 2022 Aug 25. Eur J Clin Pharmacol. 2022. PMID: 36006433
-
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran.Pharmaceutics. 2022 Jan 22;14(2):257. doi: 10.3390/pharmaceutics14020257. Pharmaceutics. 2022. PMID: 35213990 Free PMC article.
-
How Science Is Driving Regulatory Guidances.Methods Mol Biol. 2021;2342:595-629. doi: 10.1007/978-1-0716-1554-6_19. Methods Mol Biol. 2021. PMID: 34272707
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
